Handa Therapeutics LLC.: Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO Tablets
PHYRAGO Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa Pharmaceu ...
Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO (dasatinib) Tablets
TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa Pharmaceuticals, Inc. ("Handa") (6620.TWO) announced that its U.S.